{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:25:04Z","timestamp":1790357104458,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Regional Cancer Centers"},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer society","doi-asserted-by":"publisher","award":["20\u200a0156 F"],"award-info":[{"award-number":["20\u200a0156 F"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer society","doi-asserted-by":"publisher","award":["21\u200a1486 Pj"],"award-info":[{"award-number":["21\u200a1486 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Region Stockholm","award":["20200638"],"award-info":[{"award-number":["20200638"]}]},{"name":"Cancer Research Funds of Radiumhemmet","award":["194092"],"award-info":[{"award-number":["194092"]}]},{"name":"Cancer Research Funds of Radiumhemmet","award":["224023"],"award-info":[{"award-number":["224023"]}]},{"DOI":"10.13039\/100001424","name":"ALF","doi-asserted-by":"publisher","award":["2021-YF0069"],"award-info":[{"award-number":["2021-YF0069"]}],"id":[{"id":"10.13039\/100001424","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Adjuvant treatments with PD-1 and BRAF+MEK inhibitors statistically significantly prolong recurrence-free survival in stage III cutaneous melanoma. Yet, the effect on overall survival is still unclear. Based on recurrence-free survival outcomes, these treatments have been approved and widely implemented. The treatments have considerable side effects and costs, and overall survival effect remains a highly anticipated outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Clinical and histopathological parameters were obtained from the Swedish Melanoma Registry for patients diagnosed with stage III melanoma between 2016 and 2020. The patients were divided depending on if they were diagnosed before or from July 2018, based on the timepoint when adjuvant treatment was introduced in Sweden. Patients were followed up until the end of 2021. In this cohort study, melanoma-specific and overall survival were calculated using the Kaplan-Meier method and Cox-regression analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 1371 patients diagnosed with stage III primary melanoma in Sweden in 2016-2020. The 2-year overall survival rates, comparing the 634 patients in the precohort and the 737 in the postcohort, were 84.3% (95% confidence interval [CI] = 81.4% to 87.3%) and 86.1% (95% CI = 83.4% to 89.0%), respectively, with an adjusted hazard ratio of 0.91 (95% CI = 0.70 to 1.19, P\u2009=\u2009.51). Further, no statistically significant overall or melanoma-specific survival differences were seen when comparing the precohort and the postcohort in different subgroups for age, sex, or tumor characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this nationwide population-based and registry-based study, no survival benefit was detected in patients diagnosed before or after the implementation of adjuvant treatment in stage III melanoma. These findings encourage a careful assessment of the current recommendations on adjuvant treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jnci\/djad081","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T11:47:25Z","timestamp":1685015245000},"page":"1077-1084","source":"Crossref","is-referenced-by-count":31,"title":["Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study"],"prefix":"10.1093","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-4771","authenticated-orcid":false,"given":"Hildur","family":"Helgadottir","sequence":"first","affiliation":[{"name":"Department of Oncology and Pathology, Karolinska Institutet , Stockholm, Sweden"},{"name":"Theme Cancer, Karolinska University Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ny","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital , Gothenburg, Sweden"},{"name":"Department of Oncology, Sahlgrenska University Hospital , Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav J","family":"Ullenhag","sequence":"additional","affiliation":[{"name":"Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University , Uppsala, Sweden"},{"name":"Department of Oncology, Uppsala University Hospital , Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Falkenius","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology, Karolinska Institutet , Stockholm, Sweden"},{"name":"Theme Cancer, Karolinska University Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Mikiver","sequence":"additional","affiliation":[{"name":"Regional Cancer Center Southeast Sweden and Department of Clinical and Experimental Medicine, Link\u00f6ping University , Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[{"name":"Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , Gothenburg, Sweden"},{"name":"Department of Surgery, Sahlgrenska University Hospital , Gothenburg, Sweden"},{"name":"Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg , Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolin","family":"Isaksson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Surgery, Lund University , Lund, Sweden"},{"name":"Department of Surgery, Kristianstad Hopsital , Kristianstad, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"issue":"5","key":"2023110516221874800_djad081-B1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"2023110516221874800_djad081-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.001","article-title":"Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial","volume":"119","author":"Eggermont","year":"2019","journal-title":"Eur J Cancer"},{"issue":"19","key":"2023110516221874800_djad081-B3","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"2023110516221874800_djad081-B4","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"2023110516221874800_djad081-B5","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"10336","key":"2023110516221874800_djad081-B6","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"2023110516221874800_djad081-B7","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"2023110516221874800_djad081-B8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","article-title":"Adjuvant pembrolizumab versus IFNalpha2b or ipilimumab in resected high-risk melanoma","volume":"12","author":"Grossmann","year":"2022","journal-title":"Cancer Discov"},{"issue":"26","key":"2023110516221874800_djad081-B9","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"2023110516221874800_djad081-B10","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"2023110516221874800_djad081-B11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"2023110516221874800_djad081-B12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2023110516221874800_djad081-B13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"2023110516221874800_djad081-B14","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"9839","key":"2023110516221874800_djad081-B15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"2023110516221874800_djad081-B16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2016.02.029","article-title":"Prognostic instrument for survival outcome in melanoma patients: based on data from the population-based Swedish Melanoma Register","volume":"59","author":"Lyth","year":"2016","journal-title":"Eur J Cancer"},{"issue":"9","key":"2023110516221874800_djad081-B17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"2023110516221874800_djad081-B18","year":"2022"},{"issue":"3","key":"2023110516221874800_djad081-B19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ijc.30103","article-title":"Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden","volume":"139","author":"Simberg-Danell","year":"2016","journal-title":"Int J Cancer"},{"key":"2023110516221874800_djad081-B20","year":"2021"},{"issue":"36","key":"2023110516221874800_djad081-B21","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023110516221874800_djad081-B22","author":"The National Board of Health and Welfare (NBHW)","year":"2022"},{"issue":"5","key":"2023110516221874800_djad081-B23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"issue":"35","key":"2023110516221874800_djad081-B24","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.18.01219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma","volume":"36","author":"Hauschild","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl. 7","key":"2023110516221874800_djad081-B25","doi-asserted-by":"crossref","first-page":"S910","DOI":"10.1016\/j.annonc.2022.07.926","article-title":"Number needed to treat (NNT) and number needed to harm (NNH) to estimate clinical efficacy and safety of new adjuvant therapies for resected stage II-III melanoma","volume":"33","author":"Zara","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"2023110516221874800_djad081-B26","doi-asserted-by":"crossref","first-page":"e2216058","DOI":"10.1001\/jamanetworkopen.2022.16058","article-title":"Cost per event averted in cancer trials in the adjuvant setting from 2018 to 2022","volume":"5","author":"Mousavi","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2023110516221874800_djad081-B27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ijc.34462","article-title":"Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: data from two academic Italian institutions","volume":"153","author":"De Falco","year":"2023","journal-title":"Intl J Cancer"},{"key":"2023110516221874800_djad081-B28","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000888","article-title":"Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study","author":"Manzano","year":"2023","journal-title":"Melanoma Res"},{"issue":"5","key":"2023110516221874800_djad081-B29","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/jdv.18779","article-title":"Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland","volume":"37","author":"Schumann","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023110516221874800_djad081-B30","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejca.2021.08.044","article-title":"Adjuvant treatment for melanoma in clinical practice - trial versus reality","volume":"158","author":"de Meza","year":"2021","journal-title":"Eur J Cancer"},{"issue":"12","key":"2023110516221874800_djad081-B31","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N Engl J Med"},{"key":"2023110516221874800_djad081-B32","author":"RCC","year":"2023"},{"key":"2023110516221874800_djad081-B33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejca.2021.12.015","article-title":"Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: primary results of COMBI-APlus","volume":"163","author":"Atkinson","year":"2022","journal-title":"Eur J Cancer"},{"key":"2023110516221874800_djad081-B34","doi-asserted-by":"publisher","first-page":"S1408","DOI":"10.1016\/annonc\/annonc1089","article-title":"Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)","volume":"33","author":"Patel","year":"2022","journal-title":"Ann Oncol"},{"issue":"7","key":"2023110516221874800_djad081-B35","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"2023110516221874800_djad081-B36","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","article-title":"Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium","volume":"20","author":"Amaria","year":"2019","journal-title":"Lancet Oncol"},{"key":"2023110516221874800_djad081-B37","first-page":"1","article-title":"Current state of adjuvant therapy for melanoma: less is more, or more is better?","volume":"42","author":"Lao","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djad081\/51115663\/djad081.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/115\/9\/1077\/52713303\/djad081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/115\/9\/1077\/52713303\/djad081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T16:22:51Z","timestamp":1699201371000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/115\/9\/1077\/7179563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,5,25]]},"published-print":{"date-parts":[[2023,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djad081","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,5,25]]}}}